Orphazyme Wants More Time To Deal With Late-Stage Issues For Arimoclomol In EU

Other Sponsors Also Ask For A Longer Pause To CHMP’s Review Clock

Following Orphazyme’s disappointment in the US regarding its investigational drug for an ultrarare disease, the company has said it will need more time to address outstanding issues raised by EU reviewers about the same medicine.

Genetic mutation, conceptual illustration
Niemann-Pick disease Type C Is Caused By Mutations Leading To Defective NPC Protein • Source: Alamy

Orphazyme has asked for more time to address late-stage issues that the European Medicines Agency has about its EU marketing authorization application (MAA) for arimoclomol, an investigational treatment for the rare, genetic, progressively debilitating and often fatal Niemann-Pick disease type C.

The Danish company’s request to the EMA’s human medicines evaluation committee (the CHMP) for additional time comes months after arimoclomol...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography